Skip to main content

Advertisement

SpringerLink
Log in

Luminal Gastrointestinal Manifestations of Cystic Fibrosis

  • Small Intestine (D Sachar and AC Stein)
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

People with cystic fibrosis (CF) are living longer. General age-related and CF-specific gastrointestinal symptoms are increasingly recognized. In this article, we review the latest data on luminal gastrointestinal manifestations in CF.

Recent Findings

People with CF have increased incidence of gastroesophageal reflux disease symptoms and often prescribed proton-pump inhibitors (PPI). PPI use may increase risk of pulmonary exacerbations. Evidence to support gastric fundoplication to improve pulmonary outcomes is limited. Features of intestinal dysmotility are common. There are distinct differences in the gut microbiome in the CF population which may have clinical implications. CF is a possible hereditary digestive cancer syndrome, particularly in regard to colorectal cancer (CRC) with earlier incidence of CRC and advanced colonic neoplasia. Early screening colonoscopy is warranted in the CF population.

Summary

Gastrointestinal manifestations in CF are prevalent across all digestive organs. More study on the effect of interventions for symptomatic treatment and cancer screening is needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med. 2006;173(5):475–82.

    Article  PubMed  Google Scholar 

  2. MacKenzie T, Gifford AH, Sabadosa KA, Quinton HB, Knapp EA, Goss CH, et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med. 2014;161(4):233–41.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Keogh RH, Szczesniak R, Taylor-Robinson D, Bilton D. Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: a longitudinal study using UK patient registry data. J Cyst Fibros. 2018;17(2):218–27.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Cystic Fibrosis Foundation patient registry annual data report. 2018.

  5. Balfour-Lynn IM, King JA. CFTR modulator therapies - effect on life expectancy in people with cystic fibrosis. Paediatr Respir Rev. 2020.

  6. Pauwels A, Blondeau K, Dupont LJ, Sifrim D. Mechanisms of increased gastroesophageal reflux in patients with cystic fibrosis. Am J Gastroenterol. 2012;107(9):1346–53.

    Article  PubMed  Google Scholar 

  7. Blondeau K, Dupont LJ, Mertens V, Verleden G, Malfroot A, Vandenplas Y, et al. Gastro-oesophageal reflux and aspiration of gastric contents in adult patients with cystic fibrosis. Gut. 2008;57(8):1049–55.

    Article  CAS  PubMed  Google Scholar 

  8. Button BM, Roberts S, Kotsimbos TC, Levvey BJ, Williams TJ, Bailey M, et al. Gastroesophageal reflux (symptomatic and silent): a potentially significant problem in patients with cystic fibrosis before and after lung transplantation. J Heart Lung Transplant. 2005;24(10):1522–9.

    Article  PubMed  Google Scholar 

  9. Maqbool A, Pauwels A. Cystic fibrosis and gastroesophageal reflux disease. J Cyst Fibros. 2017;16(Suppl 2):S2–S13.

    Article  PubMed  Google Scholar 

  10. Kunzelmann K, Schreiber R, Hadorn HB. Bicarbonate in cystic fibrosis. J Cyst Fibros. 2017;16(6):653–62.

    Article  CAS  PubMed  Google Scholar 

  11. Posner S, Mehta K, Parish A, Niedzwiecki D, Gupta RT, Fisher DA, et al. Esophageal function tests are not associated with barium swallow findings in advanced lung disease. Dysphagia. 2020.

  12. Navarro J, Rainisio M, Harms HK, Hodson ME, Koch C, Mastella G, et al. Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. European epidemiologic registry of cystic fibrosis. Eur Respir J. 2001;18(2):298–305.

    Article  CAS  PubMed  Google Scholar 

  13. van der Doef HP, Arets HG, Froeling SP, Westers P, Houwen RH. Gastric acid inhibition for fat malabsorption or gastroesophageal reflux disease in cystic fibrosis: longitudinal effect on bacterial colonization and pulmonary function. J Pediatr. 2009;155(5):629–33.

    Article  PubMed  CAS  Google Scholar 

  14. McCrory BE, Harper HN, GL MP. Use and incidence of adverse effects of proton pump inhibitors in patients with cystic fibrosis. Pharmacotherapy. 2018.

  15. Ayoub F, Lascano J, Morelli G. Proton pump inhibitor use is associated with an increased frequency of hospitalization in patients with cystic fibrosis. Gastroenterology Res. 2017;10(5):288–93.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Dimango E, Walker P, Keating C, Berdella M, Robinson N, Langfelder-Schwind E, et al. Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis. BMC Pulm Med. 2014;14:21.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Knotts RM, Solfisburg QS, Keating C, DiMango E, Lightdale CJ, Abrams JA. Cystic fibrosis is associated with an increased risk of Barrett's esophagus. J Cyst Fibros. 2019;18(3):425–9.

    Article  PubMed  Google Scholar 

  18. Hassall E, Israel DM, Davidson AG, Wong LT. Barrett's esophagus in children with cystic fibrosis: not a coincidental association. Am J Gastroenterol. 1993;88(11):1934–8.

    CAS  PubMed  Google Scholar 

  19. Maisonneuve P, FitzSimmons SC, Neglia JP, Campbell PW 3rd, Lowenfels AB. Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study. J Natl Cancer Inst. 2003;95(5):381–7 Initial prospective cohort report of cancer incidence in in the US.

    Article  PubMed  Google Scholar 

  20. Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. J Natl Cancer Inst. 2013;105(2):122–9 Follow-up 20 year report of increased GI cancer incidience in US with increased risk in post lung transplant.

    Article  CAS  PubMed  Google Scholar 

  21. Ng SM, Moore HS. Drug therapies for reducing gastric acidity in people with cystic fibrosis. Cochrane Database Syst Rev. 2016;8:CD003424.

    Google Scholar 

  22. Sheikh SI, Ryan-Wenger NA, McCoy KS. Outcomes of surgical management of severe GERD in patients with cystic fibrosis. Pediatr Pulmonol. 2013;48(6):556–62.

    Article  PubMed  Google Scholar 

  23. Zeybel GL, Pearson JP, Krishnan A, Bourke SJ, Doe S, Anderson A, et al. Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation. J Cyst Fibros. 2017;16(1):124–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Mendez BM, Davis CS, Weber C, Joehl RJ, Fisichella PM. Gastroesophageal reflux disease in lung transplant patients with cystic fibrosis. Am J Surg. 2012;204(5):e21–6.

    Article  PubMed  Google Scholar 

  25. Jamie Dy F, Freiberger D, Liu E, Boyer D, Visner G, Rosen R. Impact of gastroesophageal reflux and delayed gastric emptying on pediatric lung transplant outcomes. J Heart Lung Transplant. 2017;36(8):854–61.

    Article  PubMed  Google Scholar 

  26. Cantu E 3rd, Appel JZ 3rd, Hartwig MG, Woreta H, Green C, Messier R, et al. J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg. 2004;78(4):1142–51 discussion −51.

    Article  PubMed  Google Scholar 

  27. Lo WK, Goldberg HJ, Wee J, Fisichella PM, Chan WW. Both pre-transplant and early post-transplant antireflux surgery prevent development of early allograft injury after lung transplantation. J Gastrointest Surg. 2016;20(1):111–8 discussion 8.

    Article  PubMed  Google Scholar 

  28. Lo WK, Goldberg HJ, Boukedes S, Burakoff R, Chan WW. Proton pump inhibitors independently protect against early allograft injury or chronic rejection after lung transplantation. Dig Dis Sci. 2018;63(2):403–10.

    Article  CAS  PubMed  Google Scholar 

  29. Strong TV, Boehm K, Collins FS. Localization of cystic fibrosis transmembrane conductance regulator mRNA in the human gastrointestinal tract by in situ hybridization. J Clin Invest. 1994;93(1):347–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Yeh KM, Johansson O, Le H, Rao K, Markus I, Perera DS, et al. Cystic fibrosis transmembrane conductance regulator modulates enteric cholinergic activities and is abnormally expressed in the enteric ganglia of patients with slow transit constipation. J Gastroenterol. 2019;54(11):994–1006.

    Article  CAS  PubMed  Google Scholar 

  31. Xue R, Gu H, Qiu Y, Guo Y, Korteweg C, Huang J, et al. Expression of cystic fibrosis transmembrane conductance regulator in ganglia of human gastrointestinal tract. Sci Rep. 2016;6:30926.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Crites KS, Morin G, Orlando V, Patey N, Cantin C, Martel J, et al. CFTR knockdown induces proinflammatory changes in intestinal epithelial cells. J Inflamm (Lond). 2015;12:62.

    Article  CAS  Google Scholar 

  33. Dorsey J, Gonska T. Bacterial overgrowth, dysbiosis, inflammation, and dysmotility in the cystic fibrosis intestine. J Cyst Fibros. 2017;16(Suppl 2):S14–23.

    Article  PubMed  Google Scholar 

  34. Corral JE, Dye CW, Mascarenhas MR, Barkin JS, Salathe M, Moshiree B. Is gastroparesis found more frequently in patients with cystic fibrosis? A systematic review. Scientifica (Cairo). 2016;2016:2918139.

    Google Scholar 

  35. Ng C, Dellschaft NS, Hoad CL, Marciani L, Ban L, Prayle AP, et al. Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by magnetic resonance imaging. J Cyst Fibros. 2020.

  36. Dellon ES, Morgan DR, Mohanty SP, Davis K, Aris RM. High incidence of gastric bezoars in cystic fibrosis patients after lung transplantation. Transplantation. 2006;81(8):1141–6.

    Article  PubMed  Google Scholar 

  37. Hirji SA, Gulack BC, Englum BR, Speicher PJ, Ganapathi AM, Osho AA, et al. Lung transplantation delays gastric motility in patients without prior gastrointestinal surgery-a single-center experience of 412 consecutive patients. Clin Transplant. 2017;31(10).

  38. Gelfond D, Ma C, Semler J, Borowitz D. Intestinal pH and gastrointestinal transit profiles in cystic fibrosis patients measured by wireless motility capsule. Dig Dis Sci. 2013;58(8):2275–81.

    Article  CAS  PubMed  Google Scholar 

  39. Malagelada C, Bendezu RA, Segui S, Vitria J, Merino X, Nieto A, et al. Motor dysfunction of the gut in cystic fibrosis. Neurogastroenterol Motil. 2020:e13883.

  40. Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. American College of G. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108(1):18–37 quiz 8.

    Article  CAS  PubMed  Google Scholar 

  41. Tonelli AR, Drane WE, Collins DP, Nichols W, Antony VB, Olson EL. Erythromycin improves gastric emptying half-time in adult cystic fibrosis patients with gastroparesis. J Cyst Fibros. 2009;8(3):193–7.

    Article  CAS  PubMed  Google Scholar 

  42. El-Chammas KI, Rumman N, Goh VL, Quintero D, Goday PS. Rectal prolapse and cystic fibrosis. J Pediatr Gastroenterol Nutr. 2015;60(1):110–2.

    Article  PubMed  Google Scholar 

  43. Stern RC, Izant RJ Jr, Boat TF, Wood RE, Matthews LW, Doershuk CF. Treatment and prognosis of rectal prolapse in cystic fibrosis. Gastroenterology. 1982;82(4):707–10.

    Article  CAS  PubMed  Google Scholar 

  44. Tabori H, Arnold C, Jaudszus A, Mentzel HJ, Renz DM, Reinsch S, et al. Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings. PLoS One. 2017;12(5):e0174463.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  45. van der Doef HP, Kokke FT, Beek FJ, Woestenenk JW, Froeling SP, Houwen RH. Constipation in pediatric cystic fibrosis patients: an underestimated medical condition. J Cyst Fibros. 2010;9(1):59–63.

    Article  PubMed  Google Scholar 

  46. Abraham JM, Taylor CJ. Cystic fibrosis & disorders of the large intestine: DIOS, constipation, and colorectal cancer. J Cyst Fibros. 2017;16(Suppl 2):S40–S9.

    Article  PubMed  Google Scholar 

  47. Bijvelds MJ, Bot AG, Escher JC, De Jonge HR. Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology. 2009;137(3):976–85.

    Article  CAS  PubMed  Google Scholar 

  48. O'Brien CE, Anderson PJ, Stowe CD. Lubiprostone for constipation in adults with cystic fibrosis: a pilot study. Ann Pharmacother. 2011;45(9):1061–6.

    Article  CAS  PubMed  Google Scholar 

  49. Arora K, Huang Y, Mun K, Yarlagadda S, Sundaram N, Kessler MM, et al. Guanylate cyclase 2C agonism corrects CFTR mutants. JCI Insight. 2017;2(19).

  50. Ahsan MK, Tchernychev B, Kessler MM, Solinga RM, Arthur D, Linde CI, et al. Linaclotide activates guanylate cyclase-C/cGMP/protein kinase-II-dependent trafficking of CFTR in the intestine. Physiol Rep. 2017;5(11).

  51. McHugh DR, Cotton CU, Moss FJ, Vitko M, Valerio DM, Kelley TJ, et al. Linaclotide improves gastrointestinal transit in cystic fibrosis mice by inhibiting sodium/hydrogen exchanger 3. Am J Physiol Gastrointest Liver Physiol. 2018;315(5):G868–G78.

    Article  CAS  PubMed  Google Scholar 

  52. Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology. 2001;120(2):354–60.

    Article  CAS  PubMed  Google Scholar 

  53. Gelfond D, Heltshe S, Ma C, Rowe SM, Frederick C, Uluer A, et al. Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation. Clin Transl Gastroenterol. 2017;8(3):e81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Houwen RH, van der Doef HP, Sermet I, Munck A, Hauser B, Walkowiak J, et al. Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS. J Pediatr Gastroenterol Nutr. 2010;50(1):38–42.

    Article  PubMed  Google Scholar 

  55. Colombo C, Ellemunter H, Houwen R, Munck A, Taylor C, Wilschanski M, et al. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. J Cyst Fibros. 2011;10(Suppl 2):S24–8.

    Article  PubMed  Google Scholar 

  56. Green J, Gilchrist FJ, Carroll W. Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis. Cochrane Database Syst Rev. 2018;6:CD012619.

    PubMed  Google Scholar 

  57. Abraham JM, Sabharwal S, Grand R, Mascarenhas M. Recommendations of the task force on distal intestinal obstruction syndrome. Bethesda, MD, USA: Cystic Fibrosis Foundation; 2016. [PortCF]

    Google Scholar 

  58. Neglia JP, FitzSimmons SC, Maisonneuve P, Schoni MH, Schoni-Affolter F, Corey M, et al. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J med. 1995;332(8):494–9 Initial report of increased GI cancers in CF.

    Article  CAS  PubMed  Google Scholar 

  59. Yamada A, Komaki Y, Komaki F, Micic D, Zullow S, Sakuraba A. Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis. Lancet Oncol. 2018;19(6):758–67 Large systematic review showing increased risk of GI cancers in CF.

    Article  PubMed  Google Scholar 

  60. Schoni MH, Maisonneuve P, Schoni-Affolter F, Lowenfels AB. Cancer risk in patients with cystic fibrosis: the European data. CF/CSG Group. J R Soc Med. 1996;89(Suppl 27):38–43.

    PubMed  PubMed Central  Google Scholar 

  61. Safaeian M, Robbins HA, Berndt SI, Lynch CF, Fraumeni JF Jr, Engels EA. Risk of colorectal cancer after solid organ transplantation in the United States. Am J Transplant. 2016;16(3):960–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Prenner S, Levitsky J. Comprehensive review on colorectal cancer and transplant. Am J Transplant. 2017;17(11):2761–74.

    Article  CAS  PubMed  Google Scholar 

  63. Fink AK, Yanik EL, Marshall BC, Wilschanski M, Lynch CF, Austin AA, et al. Cancer risk among lung transplant recipients with cystic fibrosis. J Cyst Fibros. 2017;16(1):91–7.

    Article  PubMed  Google Scholar 

  64. Maiuri L, Raia V, Piacentini M, Tosco A, Villella VR, Kroemer G. Cystic fibrosis transmembrane conductance regulator (CFTR) and autophagy: hereditary defects in cystic fibrosis versus gluten-mediated inhibition in celiac disease. Oncotarget. 2019;10(43):4492–500.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Than BLN, Linnekamp JF, Starr TK, Largaespada DA, Rod A, Zhang Y, et al. CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene. 2017;36(24):3504.

    Article  CAS  PubMed  Google Scholar 

  66. Scott P, Anderson K, Singhania M, Cormier R. Cystic fibrosis, CFTR, and colorectal cancer. Int J Mol Sci. 2020;21(8).

  67. Anderson KJ, Cormier RT, Scott PM. Role of ion channels in gastrointestinal cancer. World J Gastroenterol. 2019;25(38):5732–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Strubberg AM, Liu J, Walker NM, Stefanski CD, MacLeod RJ, Magness ST, et al. Cftr modulates Wnt/beta-catenin signaling and stem cell proliferation in murine intestine. Cell Mol Gastroenterol Hepatol. 2018;5(3):253–71.

    Article  PubMed  Google Scholar 

  69. Billings JL, Dunitz JM, McAllister S, Herzog T, Bobr A, Khoruts A. Early colon screening of adult patients with cystic fibrosis reveals high incidence of adenomatous colon polyps. J Clin Gastroenterol. 2014;48(9):e85–8 Initial report of increased colon polyps for individuals with CF at younger age.

    Article  PubMed  Google Scholar 

  70. Niccum DE, Billings JL, Dunitz JM, Khoruts A. Colonoscopic screening shows increased early incidence and progression of adenomas in cystic fibrosis. J Cyst Fibros. 2016;15(4):548–53.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Hadjiliadis D, Khoruts A, Zauber AG, Hempstead SE, Maisonneuve P, Lowenfels AB, et al. Cystic fibrosis colorectal cancer screening consensus recommendations. Gastroenterology. 2018;154(3):736–45 e14 First colorectal cancer screening guidelines in CF.

    Article  PubMed  Google Scholar 

  72. Gini A, Zauber AG, Cenin DR, Omidvari AH, Hempstead SE, Fink AK, et al. Cost effectiveness of screening individuals with cystic fibrosis for colorectal cancer. Gastroenterology. 2018;154(3):556–67 e18.

    Article  PubMed  Google Scholar 

  73. Matson AG, Bunting JP, Kaul A, Smith DJ, Stonestreet J, Herd K, et al. A non-randomised single centre cohort study, comparing standard and modified bowel preparations, in adults with cystic fibrosis requiring colonoscopy. BMC Gastroenterol. 2019;19(1):89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Ramsay KA, Sandhu H, Geake JB, Ballard E, O'Rourke P, Wainwright CE, et al. The changing prevalence of pulmonary infection in adults with cystic fibrosis: a longitudinal analysis. J Cyst Fibros. 2017;16(1):70–7.

    Article  PubMed  Google Scholar 

  75. Hatziagorou E, Orenti A, Drevinek P, Kashirskaya N, Mei-Zahav M, De Boeck K, et al. Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis-data from the European cystic fibrosis society patient registry. J Cyst Fibros. 2020;19(3):376–83.

    Article  CAS  PubMed  Google Scholar 

  76. Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519–31.

    Article  CAS  PubMed  Google Scholar 

  77. Kristensen M, Prevaes S, Kalkman G, Tramper-Stranders GA, Hasrat R, de Winter-de Groot KM, et al. Development of the gut microbiota in early life: the impact of cystic fibrosis and antibiotic treatment. J Cyst Fibros. 2020;19(4):553–61.

    Article  CAS  PubMed  Google Scholar 

  78. Burke DG, Fouhy F, Harrison MJ, Rea MC, Cotter PD, O'Sullivan O, et al. The altered gut microbiota in adults with cystic fibrosis. BMC Microbiol. 2017;17(1):58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Fridge JL, Conrad C, Gerson L, Castillo RO, Cox K. Risk factors for small bowel bacterial overgrowth in cystic fibrosis. J Pediatr Gastroenterol Nutr. 2007;44(2):212–8.

    Article  PubMed  Google Scholar 

  80. Furnari M, De Alessandri A, Cresta F, Haupt M, Bassi M, Calvi A, et al. The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin. J Gastroenterol. 2019;54(3):261–70.

    Article  CAS  PubMed  Google Scholar 

  81. Pimentel M, Saad RJ, Long MD, Rao SSC. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol. 2020;115(2):165–78.

    Article  PubMed  Google Scholar 

  82. Lisowska A, Pogorzelski A, Oracz G, Siuda K, Skorupa W, Rachel M, et al. Oral antibiotic therapy improves fat absorption in cystic fibrosis patients with small intestine bacterial overgrowth. J Cyst Fibros. 2011;10(6):418–21.

    Article  CAS  PubMed  Google Scholar 

  83. De Lisle RC, Roach E, Jansson K. Effects of laxative and N-acetylcysteine on mucus accumulation, bacterial load, transit, and inflammation in the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol. 2007;293(3):G577–84.

    Article  PubMed  CAS  Google Scholar 

  84. Peach SL, Borriello SP, Gaya H, Barclay FE, Welch AR. Asymptomatic carriage of Clostridium difficile in patients with cystic fibrosis. J Clin Pathol. 1986;39(9):1013–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Burke DG, Harrison MJ, Fleming C, McCarthy M, Shortt C, Sulaiman I, et al. Clostridium difficile carriage in adult cystic fibrosis (CF); implications for patients with CF and the potential for transmission of nosocomial infection. J Cyst Fibros. 2017;16(2):291–8.

    Article  CAS  PubMed  Google Scholar 

  86. Bauer MP, Farid A, Bakker M, Hoek RA, Kuijper EJ, van Dissel JT. Patients with cystic fibrosis have a high carriage rate of non-toxigenic Clostridium difficile. Clin Microbiol Infect. 2014;20(7):O446–9.

    Article  CAS  PubMed  Google Scholar 

  87. Monaghan TM, Negm OH, MacKenzie B, Hamed MR, Shone CC, Humphreys DP, et al. High prevalence of subclass-specific binding and neutralizing antibodies against Clostridium difficile toxins in adult cystic fibrosis sera: possible mode of immunoprotection against symptomatic C. difficile infection. Clin Exp Gastroenterol. 2017;10:169–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Egressy K, Jansen M, Meyer KC. Recurrent Clostridium difficile colitis in cystic fibrosis: an emerging problem. J Cyst Fibros. 2013;12(1):92–6.

    Article  PubMed  Google Scholar 

  89. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1–e48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Dunwoody R, Steel A, Landy J, Simmonds N. Clostridium difficile and cystic fibrosis: management strategies and the role of faecal transplantation. Paediatr Respir Rev. 2018;26:16–8.

    PubMed  Google Scholar 

  91. Hayee B, Watson KL, Campbell S, Simpson A, Farrell E, Hutchings P, et al. A high prevalence of chronic gastrointestinal symptoms in adults with cystic fibrosis is detected using tools already validated in other GI disorders. United European Gastroenterol J. 2019;7(7):881–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Lusman SS, Grand R. Approach to chronic abdominal pain in cystic fibrosis. J Cyst Fibros. 2017;16(Suppl 2):S24–31.

    Article  PubMed  Google Scholar 

  93. Adams C, Icheva V, Deppisch C, Lauer J, Herrmann G, Graepler-Mainka U, et al. Long-term pulmonal therapy of cystic fibrosis-patients with amitriptyline. Cell Physiol Biochem. 2016;39(2):565–72.

    Article  CAS  PubMed  Google Scholar 

  94. Walkowiak J, Blask-Osipa A, Lisowska A, Oralewska B, Pogorzelski A, Cichy W, et al. Cystic fibrosis is a risk factor for celiac disease. Acta Biochim Pol. 2010;57(1):115–8.

    Article  CAS  PubMed  Google Scholar 

  95. Fluge G, Olesen HV, Gilljam M, Meyer P, Pressler T, Storrosten OT, et al. Co-morbidity of cystic fibrosis and celiac disease in Scandinavian cystic fibrosis patients. J Cyst Fibros. 2009;8(3):198–202.

    Article  CAS  PubMed  Google Scholar 

  96. Holsclaw DS, Rocmans C, Shwachman H. Intussusception in patients with cystic fibrosis. Pediatrics. 1971;48(1):51–8.

    CAS  PubMed  Google Scholar 

  97. Nash EF, Stephenson A, Helm EJ, Ho T, Thippanna CM, Ali A, et al. Intussusception in adults with cystic fibrosis: a case series with review of the literature. Dig Dis Sci. 2011;56(12):3695–700.

    Article  PubMed  Google Scholar 

  98. Smyth RL, van Velzen D, Smyth AR, Lloyd DA, Heaf DP. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet. 1994;343(8889):85–6.

    Article  CAS  PubMed  Google Scholar 

  99. Nakajima K, Oshida H, Muneyuki T, Kakei M. Pancrelipase: an evidence-based review of its use for treating pancreatic exocrine insufficiency. Core Evid. 2012;7:77–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Smyth RL, Ashby D, O'Hea U, Burrows E, Lewis P, van Velzen D, et al. Fibrosing colonopathy in cystic fibrosis: results of a case-control study. Lancet. 1995;346(8985):1247–51.

    Article  CAS  PubMed  Google Scholar 

  101. Singh VK, Schwarzenberg SJ. Pancreatic insufficiency in cystic fibrosis. J Cyst Fibros. 2017;16(Suppl 2):S70–S8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Saint Louis University, St. Louis, MI, USA

    Samuel J Burton & Christine Hachem

  2. Department of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA

    James M. Abraham

Authors
  1. Samuel J Burton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christine Hachem
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James M. Abraham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James M. Abraham.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of topical collection on Small Intestine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

J Burton, S., Hachem, C. & Abraham, J.M. Luminal Gastrointestinal Manifestations of Cystic Fibrosis. Curr Gastroenterol Rep 23, 4 (2021). https://doi.org/10.1007/s11894-021-00806-5

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11894-021-00806-5

Keywords

Search

Navigation